Is Veradermics Inc (MANE) a risky stock?
As of July 23, 2026, Clavix grades Veradermics Inc (MANE) B for risk, a composite score of 73 out of 100 on an A+ to F scale, which puts MANE in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 23, 2026. Clavix regrades every trading day.
The five risk dimensions behind MANE's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MANE scores on each, as of July 23, 2026.
What's moving MANE's risk right now
Company-specific signals Clavix flags behind MANE's current grade, drawn from recent news and filings as of July 23, 2026.
Veradermics Incorporated on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair los…
Raised guidance reduces near-term uncertainty and is often a leading indicator of further upward estimate revisions.
Positive Phase 2 data de-risks the asset and positions the company for a pivotal readout in 2027, but the multi-year gap until Phase 2/3 results means monetization remains distant…
Recent MANE news
The latest headlines Clavix ingested for Veradermics Inc, newest first. These feed the news-sentiment dimension of MANE's grade.
What a B grade means
On the Clavix A+ to F scale, MANE's composite of 73 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MANE or any security. Grades are risk indicators, not predictions of return. Data may be delayed.